Compile Data Set for Download or QSAR
Report error Found 94 Enz. Inhib. hit(s) with all data for entry = 505
TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM274941(1-[2-({(2R,5R)-2- methyl-5-[(1-oxo- 1,3-dihydrofur...)
Affinity DataIC50: 12nMAssay Description: In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/12/2018
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM274911(US9556190, Example 6 | US9556190, Example 2)
Affinity DataIC50: 13nMAssay Description: In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/12/2018
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM274951(US9556190, Example 41)
Affinity DataIC50: 15nMAssay Description: In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/12/2018
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM274942(4-{[(3R,6R)-1-{[4- fluoro-2-(2H-1,2,3- triazol-2-y...)
Affinity DataIC50: 15nMAssay Description: In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/12/2018
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM274751(US9556190, Example 28 | US9556190, Example 1)
Affinity DataIC50: 16nMAssay Description: In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/12/2018
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM274939(US9556190, Example 29)
Affinity DataIC50: 16nMAssay Description: In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/12/2018
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM274953(1,1-dimethyl-4- {[(3R,6R)-6-methyl- 1-{[2-(2H-1,2,...)
Affinity DataIC50: 19nMAssay Description: In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/12/2018
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM274751(US9556190, Example 28 | US9556190, Example 1)
Affinity DataIC50: 20nMAssay Description: In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/12/2018
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM274946(4-({(3R,6R)-6-methyl- 1-[(2-pyrimidin- 2-ylphenyl)...)
Affinity DataIC50: 20nMAssay Description: In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/12/2018
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM274943(4-{[(3R,6R)-6- methyl- 1-({2-[(methyl- sulfonyl)me...)
Affinity DataIC50: 20nMAssay Description: In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/12/2018
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM274945(US9556190, Example 35)
Affinity DataIC50: 20nMAssay Description: In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/12/2018
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM274913(4-{[(3R,6R)-1-{[5-fluoro-2-(2H-1,2,3- triazol-2-yl...)
Affinity DataIC50: 23nMAssay Description: In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/12/2018
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM274952(1,1-dimethyl-4- ({(3R,6R)-6-methyl- 1-[(2-pyrimidi...)
Affinity DataIC50: 26nMAssay Description: In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/12/2018
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM274940(4-{[(3R,6R)-6- methyl-1- {[4-(2H-1,2,3- triazol-2-...)
Affinity DataIC50: 26nMAssay Description: In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/12/2018
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM274947(4-({(3R,6R)-6-methyl- 1-[(2-pyrimidin- 2-ylthiophe...)
Affinity DataIC50: 27nMAssay Description: In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/12/2018
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM274958(US9556190, Example 46)
Affinity DataIC50: 28nMAssay Description: In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/12/2018
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM274956(US9556190, Example 44)
Affinity DataIC50: 28nMAssay Description: In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/12/2018
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM274944(4-{[(3R,6R)-6- methyl-1- {[2-(2H-tetrazol-2- yl)ph...)
Affinity DataIC50: 30nMAssay Description: In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/12/2018
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM274959(US9556190, Example 47)
Affinity DataIC50: 35nMAssay Description: In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/12/2018
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM274930(US9556190, Example 20)
Affinity DataIC50: 39nMAssay Description: In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/12/2018
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM274912(4-{[(3R,6R)-1-{[5-chloro-2-(2H-1,2,3- triazol-2-yl...)
Affinity DataIC50: 42nMAssay Description: In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/12/2018
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM274918(1,1-dimethyl-4-{[(3R,6R)-6-methyl-1- {[3-methyl-2-...)
Affinity DataIC50: 43nMAssay Description: In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/12/2018
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM274935(1,1-dimethyl-4-(((3R,6R)-6-methyl-1- (2-(pyrimidin...)
Affinity DataIC50: 44nMAssay Description: In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/12/2018
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM274911(US9556190, Example 6 | US9556190, Example 2)
Affinity DataIC50: 44nMAssay Description: In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/12/2018
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM274949(US9556190, Example 39)
Affinity DataIC50: 49nMAssay Description: In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/12/2018
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM274919(4-{[(3R,6R)-1-{[4-chloro-2-(2H-1,2,3- triazol-2-yl...)
Affinity DataIC50: 54nMAssay Description: In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/12/2018
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM274914(1,1-dimethyl-4-{[(3R,6R)-6-methyl-1- {[5-methyl-2-...)
Affinity DataIC50: 54nMAssay Description: In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/12/2018
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM274920(4-{[(3R,6R)-1-{[4-fluoro-2-(2H-1,2,3- triazol-2-yl...)
Affinity DataIC50: 59nMAssay Description: In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/12/2018
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM274923(4-{[(3R,6R)-1-{[2-fluoro-6-(5-methyl- 1,2,4-oxadia...)
Affinity DataIC50: 65nMAssay Description: In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/12/2018
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM274934(4-({(3R,6R)-1-[(5-fluoro-2-pyrimidin- 2-ylphenyl)c...)
Affinity DataIC50: 72nMAssay Description: In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/12/2018
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM274924(4-{[(3R,6R)-1-{[5-fluoro-2-(5-methyl- 1,2,4-oxadia...)
Affinity DataIC50: 76nMAssay Description: In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/12/2018
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM274932(US9556190, Example 22)
Affinity DataIC50: 76nMAssay Description: In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/12/2018
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM274926(4-{[(3R,6R)-1-{[3-fluoro-2-(5-methyl- 1,2,4-oxadia...)
Affinity DataIC50: 90nMAssay Description: In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/12/2018
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM274928(4-{[(3R,6R)-1-{[5-fluoro-2-(3-methyl- 1,2,4-oxadia...)
Affinity DataIC50: 90nMAssay Description: In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/12/2018
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM274927(4-{[(3R,6R)-1-{[2-fluoro-6-(3-methyl- 1,2,4-oxadia...)
Affinity DataIC50: 102nMAssay Description: In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/12/2018
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM274931(US9556190, Example 21)
Affinity DataIC50: 109nMAssay Description: In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/12/2018
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM274936(4-({(3R,6R)-1-[(2-fluoro-6-pyrimidin- 2-ylphenyl)c...)
Affinity DataIC50: 109nMAssay Description: In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/12/2018
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM274957(US9556190, Example 45)
Affinity DataIC50: 127nMAssay Description: In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/12/2018
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM274916(4-{[(3R,6R)-1-{[3-fluoro-2-(2H-1,2,3- triazol-2-yl...)
Affinity DataIC50: 132nMAssay Description: In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/12/2018
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM274950(US9556190, Example 40)
Affinity DataIC50: 136nMAssay Description: In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/12/2018
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM274937(4-({(3R,6R)-1-[(3-fluoro-2-pyrimidin- 2-ylphenyl)c...)
Affinity DataIC50: 139nMAssay Description: In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/12/2018
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM274921(4-{[(3R,6R)-1-{[4-methoxy-2-(2H- 1,2,3-triazol-2-y...)
Affinity DataIC50: 147nMAssay Description: In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/12/2018
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM274948(US9556190, Example 38)
Affinity DataIC50: 169nMAssay Description: In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/12/2018
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM274922(4-{[(3R,6R)-1-{[6-methoxy-2-(2H- 1,2,3-triazol-2-y...)
Affinity DataIC50: 195nMAssay Description: In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/12/2018
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM274925(4-{[(3R,6R)-1-{[4-fluoro-2-(5-methyl- 1,2,4-oxadia...)
Affinity DataIC50: 232nMAssay Description: In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/12/2018
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM274929(4-{[(3R,6R)-1-{[4-fluoro-2-(3-methyl- 1,2,4-oxadia...)
Affinity DataIC50: 382nMAssay Description: In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/12/2018
Entry Details
Go to US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM274933(4-({(3R,6R)-1-[(4-fluoro-2-pyrimidin- 2-ylphenyl)c...)
Affinity DataIC50: 420nMAssay Description: In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/12/2018
Entry Details
Go to US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM274956(US9556190, Example 44)
Affinity DataIC50: 1.00E+3nMAssay Description: In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/12/2018
Entry Details
Go to US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM274941(1-[2-({(2R,5R)-2- methyl-5-[(1-oxo- 1,3-dihydrofur...)
Affinity DataIC50: 1.78E+3nMAssay Description: In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/12/2018
Entry Details
Go to US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM274914(1,1-dimethyl-4-{[(3R,6R)-6-methyl-1- {[5-methyl-2-...)
Affinity DataIC50: 2.51E+3nMAssay Description: In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/12/2018
Entry Details
Go to US Patent

Displayed 1 to 50 (of 94 total ) | Next | Last >>
Jump to: